The firm represented this biotech company in its chapter 11 case in San Francisco. The company developed knockout mice and related phenotypic, genotypic, and other data and information that it licensed to academic and commercial customers worldwide for research and development purposes. The company confirmed a plan of reorganization that repaid all of its unsecured creditors in full and reinstated all outstanding shareholder interests.

Our website uses cookies to enhance site navigation, analyze site usage, and assist in our marketing efforts. By continuing to browse this website, you agree to our Privacy Policy.